Next Article in Journal
Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
Next Article in Special Issue
Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects
Previous Article in Journal
Individualization of Radionuclide Therapies: Challenges and Prospects
Previous Article in Special Issue
Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 14
10.3390/cancers14143415
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases

by
Khalil Ramdhani
and
Arthur J. A. T. Braat
*
Department Radiology and Nuclear Medicine, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(14), 3415; https://doi.org/10.3390/cancers14143415
Submission received: 6 June 2022 / Revised: 10 July 2022 / Accepted: 12 July 2022 / Published: 14 July 2022
(This article belongs to the Special Issue Translational Research on Neuroendocrine Tumors and Experimental Tumor Therapy)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

This review provides basic insights into radioembolization, also known as selective internal radiation therapy, in patients suffering from neuroendocrine liver metastases. Radioembolization is a treatment that uses radioactive beads that are implanted intra-arterially to locally irradiate liver tumors. The available literature on radioembolization in neuroendocrine liver metastases show promising results in terms of efficacy and toxicity and will be discussed in more detail. However, data in the field of NELM need clarification, and this review also discusses the caveats, challenges and new insights when considering radioembolization in neuroendocrine liver metastases.

Abstract

At diagnosis, 21–50% of neuroendocrine tumors already have distant metastases, of which the liver is most commonly affected. Unfortunately, the presence of neuroendocrine liver metastases (NELM) is the most incriminating factor for survival. At NELM diagnosis, 60–70% of patients suffer from bilobar multifocal disease, making them ineligible for surgical resection. With limited systemic options, a clinical need for liver-directed treatments exists. Trans-arterial (bland) embolization, chemoembolization and radioembolization have been increasingly used in the treatment of NELM. In recent years, radioembolization (also known as selective internal radiation therapy) has gained attention due to promising tumor reductive results, limited toxicities and increasing scientific evidence. This review provides basic insights into radioembolization as a technique, a summary of available literature on radioembolization in NELM, and discusses caveats, challenges and new insights when considering radioembolization in NELM.

1. Introduction

Neuroendocrine neoplasms (NEN) consist of a very heterogenous group of tumors, contributing to large differences in patients’ disease burden, symptomatology, clinical and objective responses to different treatments, and prognosis. In accordance with the most recent WHO/ENETS criteria, tumor grading is the most common denominator for survival: grade 1 and 2 neuroendocrine tumors (G1-/G2NET) are regarded as well- to moderately differentiated tumors with a low Ki67 index (<3% and 3–20%, respectively); grade 3 NET (G3NET) as well- or moderately differentiated NET with high Ki67 index >20%; and neuroendocrine carcinomas (NEC) as poorly differentiated and with highly proliferative tumors (Ki67 index is most commonly >55%) [1,2,3]. However, within its heterogeneity, a well-established negative factor for survival for NEN patients is the presence of neuroendocrine liver metastases (NELM) [4]. Unfortunately, at diagnosis, 21% of all G1NET, 30% of all G2NET and 50% of all G3NET already have distant metastases, of which the liver is the most commonly affected [5,6]. In the presence of NELM, Frilling et al. provided an easy method to categorize liver involvement into three groups, based on tumor distribution in the liver [7]: from a ‘simple pattern’ (NELM involves 1–2 liver segments) to a ‘complex pattern’ (extensive unilobar disease with limited disease in the contralateral lobe) to a ‘diffuse pattern’ (bilobar or miliary disease). Whereas these ‘simple’ and ‘complex’ patterns allow surgical resection, the ‘diffuse’ pattern does not. Unfortunately, 60–70% of patients with NELM reside in the ‘diffuse pattern’ group, illustrating the clinical need for liver-directed treatments in light of the limited systemic options for NENs.
Liver-directed treatments for NELM can be divided into two categories: ablative localized treatments, e.g., radiofrequency ablation (RFA) or microwave ablation (MWA); or trans-arterial treatments, e.g., trans-arterial (bland) embolization (TAE), trans-arterial chemoembolization (TACE) and trans-arterial radioembolization (TARE). The latter technique is also known as selective internal radiation therapy (SIRT). Radioembolization is a more commonly used and simplified term but also a misnomer. Contrary to TAE and TACE, the primary effect is not to embolize vasculature and induce ischemia but to deliver high doses of radiation to tumor tissue via trans-arterial implantation. For simplicity, in this review, we will adhere to the term radioembolization. Where the localized ablative treatments can be used as an alternative to or in combination with surgical resection in the ‘simple’ and ‘complex’ disease patterns, the trans-arterial treatments are mainly applied in diffuse NELM [8,9].
Within trans-arterial treatments for NELM, radioembolization has gained a lot of attention over the last decade and reports high tumor objective response rates and limited toxicities [10]. As illustrated by the European Neuroendocrine Tumor Society (ENETS) guideline from 2016 and the European Society for Medical Oncology (ESMO) guideline from 2020, the role of radioembolization has extended, including early application as a tumor debulking treatment or as a salvage treatment in selected cases, after the failure of systemic treatments [4,11]. As NEN and NELM development are highly variable between individuals, the application of radioembolization needs to be determined on a case-by-case basis through discussions by multidisciplinary tumor boards (MDT).
This review provides insights into radioembolization as a technique, a summary of available literature on radioembolization in NELM, and a discussion of caveats, challenges and new insights when considering radioembolization in NELM.

2. How Is Radioembolization Performed?

Pre-radioembolization work-up is quite similar to other (minimally) invasive treatments, including clinical assessment, laboratory testing and imaging investigations. The minimal requirements and additional assessments that could be considered during the work-up for NELM are depicted in Table 1.
Radioembolization is a multidisciplinary treatment (involving an interventional radiologist and nuclear medicine physician) and always consists of a two-step approach (Figure 1). Firstly, a treatment simulation is performed, also known as a scout-procedure, with the administration of scout particles, either technetium-99 m macroaggregated albumin (99 mTc-MAA) or a small amount of holmium-166 microspheres (166Ho-scout dose, QuiremScout®, Quirem Medical, Deventer, the Netherlands), followed by imaging. Secondly, the actual radioembolization procedure with the administration of the therapeutic activity of particles can be used with one of three commercially available particles: yttrium-90 (90Y)-loaded glass (Theraspheres®, Boston Scientific, Marlborough, MA, USA), resin microspheres (SirSpheres®, SIRTex medical, Woburn, MA, USA), or 166Ho-microspheres (QuiremSpheres®, Quirem Medical, Deventer, the Netherlands). Thereafter, clinical, laboratory and imaging evaluation is performed for at least 6 months [9].
Prior to the first step (scout angiography), an arterial-phase contrast-enhanced CT (CECT) gives the interventional radiologist insights into the arterial variants or collaterals, which has been shown to limit procedure time and radiation exposure to the patient and personnel [12,13]. The angiography can be performed using a femoral or radial approach, and liver and tumor vasculature is assessed using digital subtraction angiography. Following the angiography assessment, additional periprocedural cone beam CTs (CBCT) are recommended as they allow the interventional radiologist to confirm total tumor coverage during the procedure and detect potential arteries supplying extrahepatic tissues, so-called culprit vessels [8]. Culprit vessels should be avoided through a more distal placement of a microcatheter beyond the origin or by coil embolization of the culprit vessel to avoid any extrahepatic deposition of radioactivity during the actual treatment. A distal placement of the microcatheter beyond the origin of a potential culprit vessel is preferred (‘limiting your footprint’); the coil embolization of culprit vessels may induce the formation of small collaterals, increasing the difficulty of treatment or causing an absolute contra-indication (inevitable extrahepatic deposition of activity) [14]. Once the interventional radiologist has determined a safe injection position(s), the scout particles are administered.
Subsequently, after the closure of the femoral or radial access, patients are taken to the nuclear medicine department for SPECT/CT imaging to exclude ‘lung shunting’ (the shunting of particles via physiological or tumor-induced arteriovenous shunts) and extrahepatic depositions of activity in the abdomen (via culprit vessels). In the event that large amounts of particles shunt towards the lungs, this is a contra-indication for treatment as this may induce (fatal) radiation pneumonitis 2–8 weeks following treatment [15]. In the case of extrahepatic depositions of activity in the gastrointestinal tract or pancreas, patients could develop radiation-induced ulcers or pancreatitis, which are difficult to treat. After excluding lung shunting and extrahepatic depositions, patients are often scheduled for the treatment procedure within 1–3 weeks [8].
Following the actual radioembolization procedure, the post-treatment imaging of the particles themselves should be performed, either with 90Y-PET/CT (or 90Y-Brehmstralung SPECT/CT) or 166Ho-SPECT/CT, to confirm the intrahepatic distribution and the absence of extrahepatic depositions of activity (Figure 1) [8].
To date, no evidence is available on the use of prophylactic medication in NELM. Based on clinical experience, standard octreotide infusion is not recommended, except in patients experiencing several carcinoid syndromes [9]. Prophylactic antibiotics should be considered in patients with a bilidigestive anastomosis but not in the general population [16]. Prophylactic proton pump inhibitors, anti-emetics and dexamethasone were commonly used at the start of radioembolization, but most experienced centers refrain from using any prophylactic medications [17].

3. SIRT in NEN: Salvage Setting

To date, many groups have collaborated to define the role of radioembolization in the treatment of NELM. The main body of evidence used to reside with many small retrospective studies consisting of mixed populations, of which the majority was in a salvage, late-stage setting. In the past 5 years, several larger retrospective studies and registries have been published further evaluating the role of radioembolization in NELM. Although presented in mixed populations, the results are very promising. Table 2 summarizes the most important scientific evidence available to date for salvage radioembolization.
Interestingly, together, these studies report over 1200 patients with quite similar findings, illustrating some degree of robustness of data and confirming the safety and efficacy of the radioembolization of NELM in a salvage setting (Table 2 and Figure 2). In addition to similar results for objective endpoints (imaging-based response and overall survival), all studies show a positive correlation with low tumor grading, obtaining DCR at first evaluation and limited intrahepatic tumor burden with OS. Several differences can also be noticed: the most interesting was the influence of the presence of extrahepatic disease. Braat et al. found a significant negative correlation with OS, whilst Schaarschmidt et al. and Wong et al. did not. However, the majority of the patients the study of Braat et al. had more extensive extrahepatic disease (66%). To date, only Braat et al. reported clinical outcomes, indicating the reduction in or resolution of hormone-related complaints in 44% and 34% of patients, respectively [9,20,21].

4. Radioembolization in Earlier Lines or Combinations Treatments

As the liver is the most commonly affected organ for NEN metastases, independent of tumor origin and often the only affected organ after the resection of a primary tumor, the application of radioembolization in an earlier line of the disease is increasingly debated. As shown in the current ENETS and ESMO guidelines, liver-directed treatments should be considered in specific cases [4,11]. To date, only one retrospective study specifically investigated the role of radioembolization in a second-line setting (following surgical resections and first-line somatostatin analogs, as shown in Figure 3). Schaarschmidt et al. showed a median hepatic PFS of 18.6 months and median global PFS of 18.8 months, which is slightly better than the results obtained in a salvage setting (Table 2). Logically, prolonged median OS was found (44.8 vs. 30.6 months) in the group treated in the second-line compared to the salvage setting group [20].
The mainstay in the treatment of metastatic disease resides in the use of systemic treatments, most commonly somatostatin analogs (SSA), peptide receptor radionuclide therapy (PRRT) and chemotherapy [4,11]. In patients with significant intrahepatic tumor burden or aggressive disease, systemic treatments tend to have less prolonged effects [22,23]. Combining a systemic and/or targeted treatment with a liver-directed treatment seems logical to boost the benefit for patients suffering from high intrahepatic tumor burden or patients with mainly NELM (liver-only or so-called “liver dominant disease”).
In previously described retrospective studies, many patients received (high-dose) SSA simultaneously with radioembolization, either for symptom control or potentially to prolong the tumor reductive effect of radioembolization. Unlike other treatments, e.g., first-line chemotherapy, no firm scientific evidence suggests a synergistic effect of SSA, and this was not separately analyzed in the aforementioned studies [24,25]. Presently, only one small study is being conducted looking at this specific combination (NCT02859064).
Currently, three smaller studies in grade 1 and 2 NETs are being conducted to combine radioembolization with systemic treatments (Table 3).
The study by Soulen et al. was the first in which 90Y resin radioembolization was combined with systemic chemotherapy capecitabin + temozolomide (CAPTEM) [26]. In this study, 21 patients with NELM of different origins were analyzed, of which the majority were treated in a second-line setting. The authors’ report showed high response rates and long survival and suggested a synergistic effect, mainly to the benefit of pNET patients. Hepatic failure due to radioembolization-induced liver disease (REILD) was encountered in one patient. To date, no follow-up data have been reported, but a follow-up study has been initiated (NCT04339036).
Kim et al. rapidly followed this with a second study combining everolimus and pasitreotide, based on an earlier study, and adding 90Y resin radioembolization [27]. This was a phase 1b study, in which the dose of everolimus was escalated, whilst the pasitreotide and radioembolization were standardized. In line with the findings of the previous RADIANT trials, a dose of 10 mg of everolimus was safe and effective, even in combination with pasitreotide and radioembolization. No additional hepatotoxicity was noticed. To date, no follow-up data have been presented, and to the knowledge of the authors, no follow-up study has been initiated.
The most recent study by Braat et al. (“HEPAR PLuS”) combined PRRT with 166Ho-radioembolization, by adding radioembolization within 20 weeks after the fourth cycle of PRRT [28]. The authors concluded that the combination was safe and effective. REILD was encountered in one patient. However, due to the heterogeneity of the group and the selection bias introduced by patient inclusion after the completion of PRRT, a patient population with a poor prognosis was selected. Five out of thirty-one (17%) of the included patients already failed PRRT (with only intrahepatic progressive disease). Nonetheless, high ORR, both RECIST 1.1 and mRECIST, and durable responses during the first year in follow-up were reported, thus the combination seems promising, and no loss in quality of life was reported (Figure 4).
Follow-up data on laboratory markers and survival were recently reported [29]. Post-PRRT bone marrow depression can be clinically challenging, but the follow-up data show that it seems safe to add radioembolization to PRRT in the absence of any hematotoxicity without significantly prolonging hematological recovery [29].
As illustrated, the data are limited; nonetheless, the data show that combining radioembolization with systemic treatments is promising and safe. The studies by Braat et al. and Frilling et al. illustrate that, following radioembolization, progressive disease and PFS occurred through the progression of extrahepatic disease or non-treated liver volumes [28,30]. Implementing radioembolization in liver-only disease as a monotherapy makes sense but becomes more complicated with the presence of extrahepatic disease. Thus, combining systemic treatments with radioembolization will benefit both treatment modalities, and further investigations are warranted.

5. Concerns, Limitations and Future Perspectives

In terms of short-term toxicity, the most feared complication is REILD, which is a form of sinusoid obstructive syndrome (SOS), caused by excessive radiation to healthy liver tissue [31]. However, the data presented in Table 2 show that REILD occurrence is incidental (0–1.8%). In patients with a history of Whipple resection and bilidigestive anastomosis, trans-arterial treatments may induce biliary ischemia (as the biliary tree is vascularized via the artery), and subsequently, may become infected by gastrointestinal bacteria in the absence of a physical barrier and retrograde colonization [8]. Especially following TACE, this is a very common complication [16]. However, liver abscesses following radioembolization in the presence of a bilidigestive anastomosis (with or without antibiotic prophylaxis) are limited. Theoretically, this seems logical as, with radioembolization, inducing ischemia is not the goal (misnomer), and the amount of biliary ischemia is significantly less pronounced than with TAE or TACE. Therefore, in patients with a bilidigestive anastomosis eligible for an embolization therapy, radioembolization is recommended, and TAE or TACE is discouraged. Other short-term complications (radiation pneumonitis <1%, gastrointestinal ulcers <2% or radiation-induced pancreatitis ~0%) are very uncommon in NEN [9].
Long-term toxicity, and in particular, long hepatotoxicity is an area of scientific debate has a lack of proper evidence [32,33,34]. Mainly in North America, concerns were raised due to suggested long-term hepatotoxicity, showing as cirrhosis-like morphology on imaging studies without clinical complaints. This was initially encountered in patients treated with radioembolization in the pre-PRRT era, who subsequently received PRRT in later disease stages [35]. Subsequent small, retrospective studies suggested that mainly patients treated with whole liver radioembolization were prone to developing long-term hepatotoxicity [36,37]. Unfortunately, these small studies could not be confirmed in the larger retrospective studies or in the prospective study by Braat et al. [9,28]. In a recent single center study, long-term hepatotoxicity was compared between patients treated with TACE and radioembolization, and no significant difference was encountered (22% vs. 29%, respectively) [32]. One may wonder whether this ‘problem’ is truly a concern. Additional issues in this scientific discussion reside in the confusion caused by the variable definitions of ‘long-term hepatotoxicity’, the discussion of confounded data (as most patients received subsequent treatments during follow-up), and the absence of one of the most important factors in radioembolization, namely in vivo particle/radiation distribution assessment, called ‘dosimetry’.
Unfortunately, a lack of dosimetry is the largest caveat of all the studies on radioembolization in NEN. As radioembolization is a two-step approach (Figure 1), physicians can use the scout procedure SPECT to predict the intrahepatic distribution of particles prior to the actual treatment. Dosimetry that is based on scout procedure SPECT allows dose escalation without increasing the risk of complications. In most centers, hepatocellular carcinoma is the number one indicator of radioembolization, and in this regard, indisputable evidence has been generated, emphasizing the importance of dosimetry [38,39,40]. In the landmark study, DOSISPHERE-1, patients treated with 90Y glass microspheres by a ‘one-size-fits-all’ approach (monocompartment model; control group) had significantly poorer results, compared to the patients that were treated in a patient-personalized fashion (multicompartment modelling), aiming for a minimum tumor-absorbed dose of 205 Gy. With multicompartment modelling, ORR increased to 71% (vs. 36%). PFS was prolonged to 6.0 months (vs. 3.4 months), and in properly dosed patients, OS was significantly prolonged to 26.6 months (vs. 7.1 months) [38].
To date, only one study evaluated dosimetry in NEN. Ebbers et al. analyzed 26 patients (128 tumors) treated with 90Y glass radioembolization in a single center. A clear dose–response relationship, independent of NEN grade, was confirmed [41]. A minimum tumor-absorbed dose of 150 Gy, and preferably more than 200 Gy, significantly increases the likelihood of receiving an RECIST 1.1-based ORR (>80%). Due to the hypervascular nature of NEN, the encountered healthy liver tissues dose was very low, limiting the possibility of establishing a dose–toxicity relationship [42]. A dose–survival relationship could be established (tumor dose >150 Gy); however, when correcting for the intrahepatic tumor burden, this relationship became non-significant. Although this was a small study, it illustrates that patient-personalized treatment based on dosimetric assessment is the way forward, in line with the developments in hepatocellular carcinoma [41].
Whereas dosimetric assessments used to be performed with in-house developed software, currently, all manufacturers of commercially available therapeutic microspheres acknowledge the importance of dosimetry, and multiple dedicated software packages are commercially available. Therefore, the application of multicompartment modelling will rapidly become standard practice.

6. Conclusions

Hepatic radioembolization is safe and effective as a monotreatment in NEN. Based on current evidence, the exact application of radioembolization in NEN care remains unknown, and the scientific debate on suggested long-term toxicities remains unresolved. The application of radioembolization should be considered on a case-by-case basis through multidisciplinary discussion. Upcoming clinical and technical developments in the field will ensure a more promising role for radioembolization in NEN care.

Author Contributions

Conceptualization, A.J.A.T.B., writing—original draft preparation, K.R.; writing—review and editing, A.J.A.T.B.; visualization, A.J.A.T.B.; supervision A.J.A.T.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

First author declares no conflict of interest. Second author has acted as a consultant for Boston Scientific and Terumo.

References

  1. Bosman, F.T.; Carneiro, F. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System, 4th ed.; IARC: Lyon, France, 2010. [Google Scholar]
  2. Capelli, P.; Fassan, M.; Scarpa, A. Pathology-grading and staging of gep-nets. Best Pract. Res. Clin. Gastroenterol. 2012, 26, 705–717. [Google Scholar] [CrossRef] [PubMed]
  3. Heetfeld, M.; Chougnet, C.N.; Olsen, I.H.; Rinke, A.; Borbath, I.; Crespo, G.; Barriuso, J.; Pavel, M.; O’Toole, D.; Walter, T.; et al. Characteristics and treatment of patients with g3 gastroenteropancreatic neuroendocrine neoplasms. Endocr. Relat. Cancer 2015, 22, 657–664. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Pavel, M.; O’Toole, D.; Costa, F.; Capdevila, J.; Gross, D.; Kianmanesh, R.; Krenning, E.; Knigge, U.; Salazar, R.; Pape, U.F.; et al. Enets consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (nen) and nen of unknown primary site. Neuroendocrinology 2016, 103, 172–185. [Google Scholar] [CrossRef] [PubMed]
  5. Yao, J.C.; Hassan, M.; Phan, A.; Dagohoy, C.; Leary, C.; Mares, J.E.; Abdalla, E.K.; Fleming, J.B.; Vauthey, J.N.; Rashid, A.; et al. One hundred years after carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states. J. Clin. Oncol. 2008, 26, 3063–3072. [Google Scholar] [CrossRef] [Green Version]
  6. Pavel, M.; Baudin, E.; Couvelard, A.; Krenning, E.; Oberg, K.; Steinmuller, T.; Anlauf, M.; Wiedenmann, B.; Salazar, R.; Barcelona Consensus Conference participants. Enets consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012, 95, 157–176. [Google Scholar] [CrossRef]
  7. Frilling, A.; Modlin, I.M.; Kidd, M.; Russell, C.; Breitenstein, S.; Salem, R.; Kwekkeboom, D.; Lau, W.Y.; Klersy, C.; Vilgrain, V.; et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014, 15, e8–e21. [Google Scholar] [CrossRef]
  8. Braat, A.J.A.T.; Smits, M.L.J.; Braat, M.N.G.J.A.; van den Hoven, A.F.; Prince, J.F.; de Jong, H.W.A.M.; van den Bosch, M.A.A.J.; Lam, M.G.E.H. 90y hepatic radioembolization: An update on current practice and recent developments. J. Nucl. Med. 2015, 56, 1079–1087. [Google Scholar] [CrossRef] [Green Version]
  9. Braat, A.J.A.T.; Kappadath, S.C.; Ahmadzadehfar, H.; Stothers, C.L.; Frilling, A.; Deroose, C.M.; Flamen, P.; Brown, D.B.; Sze, D.Y.; Mahvash, A.; et al. Radioembolization with (90)y resin microspheres of neuroendocrine liver metastases: International multicenter study on efficacy and toxicity. Cardiovasc. Intervent. Radiol. 2019, 42, 413–425. [Google Scholar] [CrossRef]
  10. Devcic, Z.; Rosenberg, J.; Braat, A.J.A.T.; Techasith, T.; Banerjee, A.; Sze, D.Y.; Lam, M.G.E.H. The efficacy of hepatic 90y resin radioembolization for metastatic neuroendocrine tumors: A meta-analysis. J. Nucl. Med. 2014, 55, 1404–1410. [Google Scholar] [CrossRef] [Green Version]
  11. Pavel, M.; Oberg, K.; Falconi, M.; Krenning, E.P.; Sundin, A.; Perren, A.; Berruti, A. Gastroenteropancreatic neuroendocrine neoplasms: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020, 31, 844–860. [Google Scholar] [CrossRef]
  12. Uliel, L.; Royal, H.D.; Darcy, M.D.; Zuckerman, D.A.; Sharma, A.; Saad, N.E. From the angio suite to the gamma-camera: Vascular mapping and 99mtc-maa hepatic perfusion imaging before liver radioembolization—A comprehensive pictorial review. J. Nucl. Med. 2012, 53, 1736–1747. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Kim, I.; Kim, D.J.; Kim, K.A.; Yoon, S.W.; Lee, J.T. Feasibility of mdct angiography for determination of tumor-feeding vessels in chemoembolization of hepatocellular carcinoma. J. Comput. Assist. Tomogr. 2014, 38, 742–746. [Google Scholar] [CrossRef] [PubMed]
  14. Abdelmaksoud, M.H.; Hwang, G.L.; Louie, J.D.; Kothary, N.; Hofmann, L.V.; Kuo, W.T.; Hovsepian, D.M.; Sze, D.Y. Development of new hepaticoenteric collateral pathways after hepatic arterial skeletonization in preparation for yttrium-90 radioembolization. J. Vasc. Interv. Radiol. 2010, 21, 1385–1395. [Google Scholar] [CrossRef] [PubMed]
  15. Stella, M.; van Rooij, R.; Lam, M.G.E.H.; de Jong, H.W.A.M.; Braat, A.J.A.T. Lung dose measured on post-radioembolization (90)y-pet/ct and incidence of radiation pneumonitis. J. Nucl. Med. 2021, 63, 1075–1080. [Google Scholar] [CrossRef]
  16. Cholapranee, A.; van Houten, D.; Deitrick, G.; Dagli, M.; Sudheendra, D.; Mondschein, J.I.; Soulen, M.C. Risk of liver abscess formation in patients with prior biliary intervention following yttrium-90 radioembolization. Cardiovasc. Intervent. Radiol. 2015, 38, 397–400. [Google Scholar] [CrossRef] [PubMed]
  17. Reinders, M.T.M.; Mees, E.; Powerski, M.J.; Bruijnen, R.C.G.; van den Bosch, M.A.A.J.; Lam, M.G.E.H.; Smits, M.L.J. Radioembolisation in Europe: A Survey Amongst CIRSE Members. Cardiovasc. Intervent. Radiol. 2018, 41, 1579–1589. [Google Scholar] [CrossRef] [Green Version]
  18. Peker, A.; Cicek, O.; Soydal, C.; Kucuk, N.O.; Bilgic, S. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn. Interv. Radiol. 2015, 21, 54–59. [Google Scholar] [CrossRef]
  19. Barbier, C.E.; Garske-Roman, U.; Sandstrom, M.; Nyman, R.; Granberg, D. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 1425–1431. [Google Scholar] [CrossRef]
  20. Schaarschmidt, B.M.; Wildgruber, M.; Kloeckner, R.; Nie, J.; Steinle, V.; Braat, A.J.A.T.; Lohoefer, F.; Kim, H.S.; Lahner, H.; Weber, M.; et al. 90y radioembolization in the treatment of neuroendocrine neoplasms: Results of an international multicenter retrospective study. J. Nucl. Med. 2022, 63, 679–685. [Google Scholar] [CrossRef]
  21. Wong, T.Y.; Zhang, K.S.; Gandhi, R.T.; Collins, Z.S.; O’Hara, R.; Wang, E.A.; Vaheesan, K.; Matsuoka, L.; Sze, D.Y.; Kennedy, A.S.; et al. Long-term outcomes following 90y radioembolization of neuroendocrine liver metastases: Evaluation of the radiation-emitting sir-spheres in non-resectable liver tumor (resin) registry. BMC Cancer 2022, 22, 224. [Google Scholar] [CrossRef]
  22. Braat, A.J.A.T.; Kwekkeboom, D.J.; Kam, B.L.R.; Teunissen, J.J.M.; de Herder, W.W.; Dreijerink, K.M.A.; van Rooij, R.; Krijger, G.C.; de Jong, H.W.A.M.; van den Bosch, M.A.A.J.; et al. Additional hepatic 166ho-radioembolization in patients with neuroendocrine tumours treated with 177lu-dotatate; a single center, interventional, non-randomized, non-comparative, open label, phase ii study (hepar plus trial). BMC Gastroenterol. 2018, 18, 84. [Google Scholar] [CrossRef]
  23. Strosberg, J.; Kunz, P.L.; Hendifar, A.; Yao, J.; Bushnell, D.; Kulke, M.H.; Baum, R.P.; Caplin, M.; Ruszniewski, P.; Delpassand, E.; et al. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)lu-dotatate: An analysis of the netter-1 study. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 2372–2382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Lepage, C.; Dahan, L.; Bouarioua, N.; Toumpanakis, C.; Legoux, J.L.; Le Malicot, K.; Guimbaud, R.; Smith, D.; Tougeron, D.; Lievre, A.; et al. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. Dig. Liver Dis. 2017, 49, 568–571. [Google Scholar] [CrossRef] [PubMed]
  25. Lepage, C.; Phelip, J.M.; Lièvre, A.; Le Malicot, K.; Tougeron, D.; Dahan, L.; Toumpanakis, C.; Di Fiore, F.; Bohas, C.L.; Borbath, I.; et al. 1163p lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (nets): An international double-blind, placebo-controlled randomized phase ii trial. Ann. Oncol. 2020, 31, S774. [Google Scholar] [CrossRef]
  26. Soulen, M.C.; van Houten, D.; Teitelbaum, U.R.; Damjanov, N.; Cengel, K.A.; Metz, D.C. Safety and feasibility of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors. Pancreas 2018, 47, 980–984. [Google Scholar] [CrossRef] [PubMed]
  27. Kim, H.S.; Shaib, W.L.; Zhang, C.; Nagaraju, G.P.; Wu, C.; Alese, O.B.; Chen, Z.; Brutcher, E.; Renfroe, M.; El-Rayes, B.F. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer 2018, 124, 1992–2000. [Google Scholar] [CrossRef] [Green Version]
  28. Braat, A.J.A.T.; Bruijnen, R.C.G.; van Rooij, R.; Braat, M.N.G.J.A.; Wessels, F.J.; van Leeuwaarde, R.S.; van Treijen, M.J.C.; de Herder, W.W.; Hofland, J.; Tesselaar, M.E.T.; et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (hepar plus): A single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020, 21, 561–570. [Google Scholar] [CrossRef]
  29. Ebbers, S.C.; Brabander, T.; Tesselaar, M.E.T.; Hofland, J.; Braat, M.N.G.J.A.; Wessels, F.J.; Barentsz, M.W.; Lam, M.G.E.H.; Braat, A.J.A.T. Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy. EJNMMI Res. 2022, 12, 7. [Google Scholar] [CrossRef]
  30. Frilling, A.; Clift, A.K.; Braat, A.J.A.T.; Alsafi, A.; Wasan, H.S.; Al-Nahhas, A.; Thomas, R.; Drymousis, P.; Habib, N.; Tait, P.N. Radioembolisation with 90y microspheres for neuroendocrine liver metastases: An institutional case series, systematic review and meta-analysis. HPB 2019, 21, 773–783. [Google Scholar] [CrossRef]
  31. Braat, M.N.G.J.A.; van Erpecum, K.J.; Zonnenberg, B.A.; van den Bosch, M.A.A.J.; Lam, M.G.E.H. Radioembolization-induced liver disease: A systematic review. Eur. J. Gastroenterol. Hepatol. 2017, 29, 144–152. [Google Scholar] [CrossRef]
  32. Currie, B.M.; Nadolski, G.; Mondschein, J.; Dagli, M.; Sudheendra, D.; Stavropoulos, S.W.; Soulen, M.C. Chronic hepatotoxicity in patients with metastatic neuroendocrine tumor: Transarterial chemoembolization versus transarterial radioembolization. J. Vasc. Interv. Radiol. 2020, 31, 1627–1635. [Google Scholar] [CrossRef] [PubMed]
  33. Padia, S.A. Radioembolization versus chemoembolization for neuroendocrine metastases. J. Vasc. Interv. Radiol. 2021, 32, 482–483. [Google Scholar] [CrossRef]
  34. Currie, B.M.; Nadolski, G.; Soulen, M.C. Response letter to correspondence regarding chronic hepatotoxicity in patients with metastatic neuroendocrine tumor: Transarterial chemoembolization versus transarterial radioembolization. J. Vasc. Interv. Radiol. 2021, 32, 483–484. [Google Scholar] [CrossRef] [PubMed]
  35. Riff, B.P.; Yang, Y.X.; Soulen, M.C.; Pryma, D.A.; Bennett, B.; Wild, D.; Nicolas, G.; Teitelbaum, U.R.; Metz, D.C. Peptide receptor radionuclide therapy-induced hepatotoxicity in patients with metastatic neuroendocrine tumors. Clin. Nucl. Med. 2015, 40, 845–850. [Google Scholar] [CrossRef] [PubMed]
  36. Su, Y.K.; Mackey, R.V.; Riaz, A.; Gates, V.L.; Benson, A.B., 3rd; Miller, F.H.; Yaghmai, V.; Gabr, A.; Salem, R.; Lewandowski, R.J. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J. Vasc. Interv. Radiol. 2017, 28, 1520–1526. [Google Scholar] [CrossRef]
  37. Tomozawa, Y.; Jahangiri, Y.; Pathak, P.; Kolbeck, K.J.; Schenning, R.C.; Kaufman, J.A.; Farsad, K. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J. Vasc. Interv. Radiol. 2018, 29, 858–865. [Google Scholar] [CrossRef] [Green Version]
  38. Garin, E.; Tselikas, L.; Guiu, B.; Chalaye, J.; Edeline, J.; de Baere, T.; Assenat, E.; Tacher, V.; Robert, C.; Terroir-Cassou-Mounat, M.; et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (dosisphere-01): A randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol. Hepatol. 2021, 6, 17–29. [Google Scholar] [CrossRef]
  39. Hermann, A.L.; Dieudonne, A.; Ronot, M.; Sanchez, M.; Pereira, H.; Chatellier, G.; Garin, E.; Castera, L.; Lebtahi, R.; Vilgrain, V.; et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)y in the sarah study. Radiology 2020, 296, 673–684. [Google Scholar] [CrossRef]
  40. Lam, M.G.E.H.; Garin, E.; Maccauro, M.; Kappadath, S.C.; Sze, D.Y.; Turkmen, C.; Cantasdemir, M.; Haste, P.; Herrmann, K.; Alsuhaibani, H.S.; et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with yttrium-90: The target study. Eur. J. Nucl. Med. Mol. Imaging 2022, 1–13. [Google Scholar] [CrossRef]
  41. Ebbers, S.C.; van Roekel, C.; Braat, M.N.G.J.A.; Barentsz, M.W.; Lam, M.G.E.H.; Braat, A.J.A.T. Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 1700–1710. [Google Scholar] [CrossRef]
  42. Sommer, W.H.; Ceelen, F.; Garcia-Albeniz, X.; Paprottka, P.M.; Auernhammer, C.J.; Armbruster, M.; Nikolaou, K.; Haug, A.R.; Reiser, M.F.; Theisen, D. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur. Radiol. 2013, 23, 3094–3103. [Google Scholar] [CrossRef] [PubMed]
Cancers 14 03415 g001 550
Figure 1. Graphical representation of a radioembolization treatment.
Figure 1. Graphical representation of a radioembolization treatment.
Cancers 14 03415 g001
Cancers 14 03415 g002 550
Figure 2. Radioembolization in a patient with an irresectable grade 1 pNET/insulinoma, suffering from frequent hypoglycemic crises (even with continuous enteral feeding and medication) after failure of somatostatin analogs (SSA), chemotherapy with capecitabine + temozolomide (CAPTEM) and peptide receptor radionuclide therapy (PRRT). Left: Pretreatment 68Ga-DOTATOC PET/CT depicting the pNET and liver metastases. Treated with a whole liver radioembolization in a single session, with 90Y resin microspheres (monocompartment modelling, 50 Gy target volume dose). Within two weeks, this clinically resulted in a significant reduction in insulin production, allowing the cessation of enteral feeding and a dose reduction in supportive medication. Right: Post-treatment 68Ga-DOTATOC PET/CT 6 months after treatment showing evident tumor reduction. Although clinically stable for a long time, follow-up imaging showed a minor progression of disease after 3.2 years.
Figure 2. Radioembolization in a patient with an irresectable grade 1 pNET/insulinoma, suffering from frequent hypoglycemic crises (even with continuous enteral feeding and medication) after failure of somatostatin analogs (SSA), chemotherapy with capecitabine + temozolomide (CAPTEM) and peptide receptor radionuclide therapy (PRRT). Left: Pretreatment 68Ga-DOTATOC PET/CT depicting the pNET and liver metastases. Treated with a whole liver radioembolization in a single session, with 90Y resin microspheres (monocompartment modelling, 50 Gy target volume dose). Within two weeks, this clinically resulted in a significant reduction in insulin production, allowing the cessation of enteral feeding and a dose reduction in supportive medication. Right: Post-treatment 68Ga-DOTATOC PET/CT 6 months after treatment showing evident tumor reduction. Although clinically stable for a long time, follow-up imaging showed a minor progression of disease after 3.2 years.
Cancers 14 03415 g002
Cancers 14 03415 g003 550
Figure 3. Radioembolization in a patient with oligoprogression of a liver metastases in liver segment 7 (A), previously treated with 4 cycles of PRRT after a Whipple resection of the primary non-functional pNET. No disease elsewhere on 68Ga-DOTATOC PET/CT. Gadolinium-enhanced MRI shows a larger lesion with multiple satellite lesions in its vicinity (with diffusion restriction). Surgical resection and ablative techniques were considered unsuitable, thus, MDT decided on a selective ablative radioembolization. (B) Post-treatment 90Y PET/CT (300 Gy target volume dose in segment 7), revealing a high accumulation of particles in all metastases. (C) MRI 3 months after treatment showing complete tumor necrosis of all metastases and some radiation-induced changes in the surrounding healthy liver tissue.
Figure 3. Radioembolization in a patient with oligoprogression of a liver metastases in liver segment 7 (A), previously treated with 4 cycles of PRRT after a Whipple resection of the primary non-functional pNET. No disease elsewhere on 68Ga-DOTATOC PET/CT. Gadolinium-enhanced MRI shows a larger lesion with multiple satellite lesions in its vicinity (with diffusion restriction). Surgical resection and ablative techniques were considered unsuitable, thus, MDT decided on a selective ablative radioembolization. (B) Post-treatment 90Y PET/CT (300 Gy target volume dose in segment 7), revealing a high accumulation of particles in all metastases. (C) MRI 3 months after treatment showing complete tumor necrosis of all metastases and some radiation-induced changes in the surrounding healthy liver tissue.
Cancers 14 03415 g003
Cancers 14 03415 g004 550
Figure 4. Patient with a grade 1 pNET with liver metastases, who participated in the HEPAR PLuS trial. (A) Baseline CT prior to PRRT with 4 cycles of 7.4 GBq 177Lu-DOTATATE. (B) CT 3 months after PRRT depicting evident progressive intrahepatic disease. (C) CT 3 months after additional 166Ho-radioembolization showing increased necrosis, size reduction and reduced enhancement of neuroendocrine liver metastases, and stable disease according to RECIST 1.1 (−22%). (D) CT 12 months after additional 166Ho-radioembolization showing advancing partial response according to RECIST 1.1 (−44%) and tumor reduction.
Figure 4. Patient with a grade 1 pNET with liver metastases, who participated in the HEPAR PLuS trial. (A) Baseline CT prior to PRRT with 4 cycles of 7.4 GBq 177Lu-DOTATATE. (B) CT 3 months after PRRT depicting evident progressive intrahepatic disease. (C) CT 3 months after additional 166Ho-radioembolization showing increased necrosis, size reduction and reduced enhancement of neuroendocrine liver metastases, and stable disease according to RECIST 1.1 (−22%). (D) CT 12 months after additional 166Ho-radioembolization showing advancing partial response according to RECIST 1.1 (−44%) and tumor reduction.
Cancers 14 03415 g004
Table
Table 1. Pre-radioembolization work-up.
Table 1. Pre-radioembolization work-up.
Clinical AssessmentLaboratory TestingImaging Work-Up
Minimal
ECOG performance scoreBilirubin, ALP, AST, ALT, albumin gdMRI/CECT for intrahepatic tumor load 1
Signs of hepatic dysfunction (Child–Pugh score)Creatinine, eGFREarly-phase CECT for arterial vasculature
NET hormone-related symptomsTumor markers (e.g., CgA, gastrin)
Additional
In selected cases, Fibroscan or gastroscopy to assess esophageal varicesHb, hematocrit, WBC, plateletsSSTR-PET/CT for total body tumor load 1
Coagulation (e.g., Prothrombin time or INR)FDG-PET/CT for tumor grade distinction, excluding aggressive disease.
Legend: ECOG = Eastern Cooperative Oncology Group, NET = neuroendocrine tumor, eGFR = estimated glomerular filtration rate; ALP = alkaline phosphatase, AST = aspartate aminotransferase, ALT = alanine aminotransferase, CgA = chromogranin A, Hb = hemoglobin, WBC = white blood cell count, INR = international normalized ratio, gdMRI = gadolinium-enhanced magnetic resonance imaging, CECT = contrast-enhanced computed tomography, SSTR = somatostatin receptor; PET/CT = positron emission tomography/computed tomography, FDG = fluorodeoxyglucose. 1 tumor load = fractional tumor involvement.
Table
Table 2. Landmark papers on salvage radioembolization in NEN.
Table 2. Landmark papers on salvage radioembolization in NEN.
YearNORR *DCR *PFSOSREILD
%%MonthsMonthsn (%)
Devcic et al. † [10]20144355086NR28.5NR
Peker et al. [18]2015384683NR390
Barbier et al. [19]2016545494NR34.81 (1.8)
Braat et al. [9]20192441691NR312 (0.8)
4391
Schaarschmidt et al. [20]202229741.383.515.930.62 (0.8)
Wong et al. [21]2022170366925331 (0.6)
Legend: NR = not reported, n = number of procedures, ORR = objective response rate, defined as complete + partial response, DCR = disease control rate, defined as ORR + stable disease, PFS = median or mean progression free survival, OS = median or mean overall survival, REILD = radioembolization-induced liver disease. * Response within or at 3 months according to RECIST 1.1 in regular font and in italics according to mRECIST. † Only meta-analyses on data before 2014, and other studies presented are original articles.
Table
Table 3. Combination treatments with radioembolization in NEN.
Table 3. Combination treatments with radioembolization in NEN.
AuthorYearnPopulationProceduresORR *PFS †OS
Soulen
et al. [26]		201821Grade 2 NELMcapecitabin 600 mg/m2 twice daily for 14 days
temozolomide 150 to 200 mg/m2 in divided on days 10 to 14.
90Y resin radioembolization 7th day of cycle 2		74%NRNR
Kim
et al. [27]		201813Grade 1 + 2 NELM3 + 3 dose escalation of everolimus 2,5–5–10 mg
Pasitreotide 600 µg twice daily
90Y resin radioembolization day 9 and 37		46%18.646.3
Braat
et al. [28]		202031Grade 1 + 2 NELMStandard 4 cycles of 7.4 GBq 177Lu-PRRT
166Ho-radioembolization <20 weeks after 4th PRRT		43%30.140.8
Legend: n = number of patients, ORR = objective response rate, defined as complete + partial response according to RECIST 1.1, PFS = median progression-free survival, PRRT = peptide receptor radionuclide therapy with lutetium-177-DOTATATE, NR = not reached. * Intrahepatic ORR. † Progression-free survival in months.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Ramdhani, K.; Braat, A.J.A.T. The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases. Cancers 2022, 14, 3415. https://doi.org/10.3390/cancers14143415

AMA Style

Ramdhani K, Braat AJAT. The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases. Cancers. 2022; 14(14):3415. https://doi.org/10.3390/cancers14143415

Chicago/Turabian Style

Ramdhani, Khalil, and Arthur J. A. T. Braat. 2022. "The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases" Cancers 14, no. 14: 3415. https://doi.org/10.3390/cancers14143415

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop